期刊文献+

不同剂量辛伐他汀治疗冠心病的临床疗效观察 被引量:6

Effect of simvastatin dosage in treating coronary heart disease
下载PDF
导出
摘要 目的观察冠状动脉粥样硬化性心脏病患者使用不同剂量辛伐他汀的疗效、安全性、对血脂斑块生长及心血管事件的影响。方法将血脂总胆固醇(TC)≥4.68mmol/L和(或)低密度脂蛋白胆固醇(LDL-C)≥2.6 mmol/L,B超检查存在不同程度颈动脉斑块形成的临床诊断为冠心病的患者(126例)按随机原则分别入选辛伐他汀80mg组(强化治疗剂量)、40mg组与20mg组(常用处方剂量)。于服药后12周及24周复查血脂,B超复查颈动脉斑块,并对心血管事件作随访登记。结果辛伐他汀80mg、40mg与20mg均能有效地降低冠心病患者血清TC及LDL-C水平,其中80mg剂量组在降TC和降LDL-C及减少心血管事件发生率方面均明显优于20mg剂量组,40mg剂量组疗效介于两组之间,三者间均存在显著差异。80mg剂量组的颈动脉斑块缩小,而40mg剂量组及20mg剂量组无颈动脉斑块缩小。三种剂量在不良反应方面无明显差异。结论辛伐他汀强化治疗剂量在治疗冠心病方面明显优于常用处方剂量;强化治疗剂量可以逆转颈动脉斑块发展。 Objective To observe the efficacy and safety of three different dosage of simvastatin in the treatment of patients with coronary heart disease and the effect in treating carotid plaques and risk of major events. Methods One hundred and twenty-six patients with different degrees of carotid plaques detected by ultrasonic, whose total cholesterol (TC) was over 4.68mmol/L or low-density lipoprotein cholesterol ( LDL-C) over 2.6 mmol/L, were entered the study and randomized to three groups: 80mg-group ( intensification dosage, n = 42 ), 40mg-group( n = 39 ) and 20mg-group ( common prescription dosage, n = 45). At the 12th week and the 24th week, lipid levels were determined and carotid plaques were detec ted by ultrasonic again. During the following-up, all cardiovascular events and adverse events were recorded. Results Levels of LDL-C and TC reduced significantly in 80mg-group, 40mg-group and 20mg-group. While the effect in 80mg-group was better than that in the other groups. There was lower rate of cardiovascular events in 80mg-group than that in the other groups (P 〈 0.05). The plaques in 80mg-group were significantly reduced (P 〈0.01) compared with those before treatment. There was little difference in clinical adverse events between in 80mg-group and in the other groups. Conclusion Intensification dosage of the HMG-CoA reductase inhibitor simvastatin is better than common prescription dosage in treating coronary heart disease and the former can converse the carotid plaques development.
出处 《中国心血管杂志》 2006年第5期361-364,共4页 Chinese Journal of Cardiovascular Medicine
关键词 冠心病 脂类及降脂药物 颈动脉斑块 强化治疗 Coronary heart disease Lipid and lipid-lowering agents Carotid plaques Intensificational treatment
  • 相关文献

参考文献8

  • 1Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature [J]. J Circulation, 1979,59:607.
  • 2Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastation in 5963 people with diabetes, a randomized placebo-controlled trial[J]. lancet, 2003,361:2005-2016.
  • 3熊全庚,范木林,郭跃华.早期强化辛伐他汀治疗急性冠状动脉综合征的研究[J].临床心血管病杂志,2004,20(12):710-712. 被引量:25
  • 4Fichtlscherer S, Rosenberger G, Waiter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity inpatients with coronary artery disease[J].Circulation, 2005,102:1000-1006.
  • 5Criby M, Nordin FG, Shah PK, et al. Pravastatin treament increases collagen content, inflammation, metalloproteinases and cell death in human carotid plaques: implications for plaque stabilization [J]. J Circulation,2003, 103: 926-933.
  • 6Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human ahterosclerotic lesions[J]. J Circulation, 2004, 104: 249-252.
  • 7Garmendia F, Brown AS, Reiber I, et al . Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study):Getting to Appropriate LDLC Levels with Simvastatin [J]. J Curr Med Res Opin,2002,16:208-219.
  • 8Chung N, Cho SY, Choi DH, et al. a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease: Simvastatin Treats Asians to Target Trial[J]. J Clin Ther, 2001,23: 858-870.

二级参考文献12

  • 1Dupuis J, Tardif J C, Cernacek P, et al. Theroux cholesterol reduction rapidly improves endothelial function of the RECIFE (Reduction of cholesterol in ische-mial and function of the endothelium) trial. Circulation,1999,99: 3227- 3233.
  • 2The Long-term Intervention with Pravastatin in Ischaemic Disease(LIPID) study group. Prevention of cardiovascular events and a broad range of initial cholesterol levels. N EnglJ Med, 1998,339:1349-1357.
  • 3Pederson J R, Olsson A G, Faergeman V, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 1998,97:1453-1460.
  • 4FlakerG C, Warnica J W, Sacks F M,et al. For the Cholesterol and Recurrent Event(CARE) investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol, 1999,34:106- 112.
  • 5Schwartz G G, Olsson A G, Ezekowitz M D, et al.Effects of atorvastatin on early recurrent ische mic events in acute coronary syndrome. The MIRACL study: A randomized controlled trial. JAMA, 2001,285:1711-1718.
  • 6Maron D J, Fazio S, Linton M F. Current perspectives on statins. Circulation, 2000,101: 207- 213.
  • 7Bustos C, Hernandez-Presa M A, Ortego M, et al.HMG-GoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol, 1998,32:2057-2064.
  • 8Laufs U, Liao J K. Post-transcriptional regulation of endothelial nitric oxide synthasc mRNA stability by Rho GTPase. J Biol Chem, 1998,273:24266-24271.
  • 9Williams J K, Sukova G K, Herrington D M, et al.Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol, 1998,31: 684- 691.
  • 10Rose.,RS,胡予.他汀类药物的抗粥样血栓特性对心血管事件减少的意义[J].美国医学会杂志(中文版),1999,18(3):110-115. 被引量:20

共引文献24

同被引文献60

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部